Fig. 4From: Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trialsProportion of participants reporting that their migraine was “much better” or “very much better” on the PGIC scale at 2 h after initial dose in TIR (a) and TIR due to insufficient efficacy (b) groups. OR, odds ratio; PGIC, Patient Global Impression of Change; TIR, triptan insufficient responder. P-values are based on logistic regression with treatment group, use of medication for migraine prevention, and baseline headache severity as covariatesBack to article page